NL-OMON55389RecruitingNot Applicable
Establishing organoids from metastatic pancreatic cancer patients, the OPT-I study - OPT-I
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •- Patients older than 18 years
- •- Diagnosed with locally advanced pancreatic cancer or metastatic pancreatic
- •- Able to understand the information given
- •- WHO 0-2
Exclusion Criteria
- •- Unfit for biopsies & blood analyses in palliative chemotherapy studies
- •- Not able to give informed consent (language, intellectual capacities, etc.)
Investigators
Similar Trials
Unknown
Not Applicable
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.Carcinoma, Pancreatic DuctalNCT03500068Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)30
Terminated
Phase 1
Investigation of gemcitabine combined with temsirolimus, in patients with inoperable or metastatic pancreatic cancer. A phase I-II study by the Hellenic Cooperative Oncology Group with biomarker evaluation (HE3/07)Patients with inoperable or metastatic pancreatic cancerCancer - PancreaticACTRN12611000643976Hellenic Cooperative Oncology Group85
Completed
Not Applicable
Patient-derived Organoids Drug Screen in Pancreatic CancerPancreas CancerPancreas NeoplasmPancreas AdenocarcinomaPancreatic NeoplasmsPancreatic AdenocarcinomaPancreatic CancerNCT05351983Prof. Dr. med. Dres. h.c. Jan Schmidt, MME60
Completed
Not Applicable
Development of cytological analysis of pancreatic cancer using homology technologypancreatic cancerJPRN-UMIN000044462Mie University180
Not yet recruiting
Not Applicable
Botulinum toxin (BOTOX®) to prevent post-operative pancreatic fistula in patients who undergo distal pancreatectomy. (PROFIT study)Pancreatic cancerNL-OMON22900Erasmus MC50